The level of fatigue in a patient with Hodgkin lymphoma (HL) is independent of the patient’s tumor stage or cancer treatment method, and the severity of long-term fatigue is associated primarily with fatigue levels at baseline, according to a study published in Lancet Oncology (2016;17[10]:1453-1462, PMID: 27612583).
Severe acute and persistent fatigue in survivors of HL is estimated at 2.5 to three times higher than in the general population. Since 80% to 90% of patients with HL today are